Regeneron Pharmaceuticals, Inc.
CRISPR/CAS DROPOUT SCREENING PLATFORM TO REVEAL GENETIC VULNERABILITIES ASSOCIATED WITH TAU AGGREGATION

Abstract:

Cas-protein-ready tau bio sensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic vulnerability associated with tau aggregation are provided.